| KELUN |
KELUN |
90%
|
The Kelun CR-001 License Agreement includes the provision of the initial supply of CR-001 drug product by the Company |
| BNTX |
BioNTech SE |
72%
|
Reciprocal relationship from BNTX graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from CBIO graph: ave no significant experience as a … |
| BNTX |
BioNTech SE |
72%
|
ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials … |
| CMPX |
Compass Therapeutics, Inc. |
72%
|
ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials … |
| CMPX |
Compass Therapeutics, Inc. |
72%
|
Reciprocal relationship from CMPX graph: Reciprocal relationship from CBIO graph: ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because … |
| SMMT |
Summit Therapeutics Inc. |
72%
|
Reciprocal relationship from SMMT graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from SMMT graph: Reciprocal relationship from CBIO graph: ave no significant experience as a … |
| SMMT |
Summit Therapeutics Inc. |
72%
|
ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials … |
| SNYNF |
Sanofi |
72%
|
d parties or counterclaim against such third parties or negotiate more advantageous settlement parameters. Further, any issued patents that we may license or own covering our programs could be narrow… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from SNYN… |
| BIONTECH-SE-LANOVA-MEDICINES-LTD |
BIONTECH-SE-LANOVA-MEDICINES-LTD |
62%
|
ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials … |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
as compared to March 31, 2025. 33 Table of Contents Interest Expense The following table summarizes our interest expense for the periods presented (in thousands): Three Months Ended March 31, 2026 Th… |
| CRESCENT-BIOPHARMA-OPERATING-COMPANY-LLC |
CRESCENT-BIOPHARMA-OPERATING-COMPANY-LLC |
62%
|
s CR-003, a product designation which previously referred to a preclinical ADC asset under the Amended and Restated ADC Discovery and Option Agreement, dated April 28, 2025 (the “ADC Paragon Option A… |
| EQUITY-INCENTIVE-PLAN-THE-CRESCENT-BIOPHARMA-INC |
EQUITY-INCENTIVE-PLAN-THE-CRESCENT-BIOPHARMA-INC |
62%
|
Pre-Funded Warrant), for an aggregate purchase price of approximately $ 185.0 million. The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants … |
| HONG-KONG-LIMITED |
HONG-KONG-LIMITED |
62%
|
ctions on our current or future licensors’ abilities to develop products that could be competitive with ours, these restrictions may not prevent the possible future license or development by our curr… |
| MERCK-BRISTOL-MYERS-SQUIBB-GENENTECH-ASTRAZENECA |
MERCK-BRISTOL-MYERS-SQUIBB-GENENTECH-ASTRAZENECA |
62%
|
ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials … |
| NANO-DIMENSION-USA-INC |
NANO-DIMENSION-USA-INC |
62%
|
lly reasonable efforts to develop and commercialize at least one CR-001 product candidate in the SKB Territory. Kelun paid or will pay the Company the following: • $ 20.0 million within 30 days of si… |
| NNDM |
Nano Dimension Ltd. |
62%
|
Reciprocal relationship from NNDM graph: Reciprocal relationship from CBIO graph: Reciprocal relationship from NNDM graph: Reciprocal relationship from CBIO graph: lly reasonable efforts to develop a… |
| PARAGON-THERAPEUTICS-INC |
PARAGON-THERAPEUTICS-INC |
62%
|
s CR-003, a product designation which previously referred to a preclinical ADC asset under the Amended and Restated ADC Discovery and Option Agreement, dated April 28, 2025 (the “ADC Paragon Option A… |
| PARASCENT-HOLDING-LLC |
PARASCENT-HOLDING-LLC |
62%
|
ave no significant experience as a company in initiating, conducting, or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials … |
| SICHUAN-KELUN-BIOTECH-BIOPHARMACEUTICAL-CO-LTD |
SICHUAN-KELUN-BIOTECH-BIOPHARMACEUTICAL-CO-LTD |
62%
|
s CR-003, a product designation which previously referred to a preclinical ADC asset under the Amended and Restated ADC Discovery and Option Agreement, dated April 28, 2025 (the “ADC Paragon Option A… |
| WUXI-BIOLOGICS-IRELAND-LIMITED |
WUXI-BIOLOGICS-IRELAND-LIMITED |
62%
|
rch 31, 2026, the total remaining operating lease payments included in the measurement of lease liabilities was as follows (in thousands): Period ended December 31 2026 (remainder of the year) $ 441 … |
